We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Clinical Introduction
-
1. Frontotemporal dementia
- Prof. Bruce Miller
-
2. Parkinson disease
- Prof. Stanley Fahn
-
3. Atypical parkinsonian syndromes
- Dr. David Burn
-
4. Huntington's disease
- Prof. Roger Barker
- Neuroimaging
-
5. Molecular brain imaging (PET) in diseases with dementia
- Prof. Karl Herholz
- Pathology, Genetic and Molecular Aspects (1)
-
6. A molecular understanding of Alzheimer's disease
- Prof. John Hardy
-
7. Neuropathology of neurodegenerative disorders
- Prof. Jillian Kril
-
9. Ubiquitination and Alzheimer related disorders
- Prof. John Mayer
- Pathology, Genetic and Molecular Aspects (2)
-
10. The molecular biology of Huntington's disease
- Prof. David C. Rubinsztein
-
11. Metals, oxidative stress and neurodegeneration
- Prof. Ashley Bush
- Latest Developments in the Field
-
12. Animal models of tauopathy
- Prof. David Westaway
-
13. Parkinson's disease and transplants
- Prof. Roger Barker
- Archived Lectures *These may not cover the latest advances in the field
-
14. Neuropathology of neurodegenerative disorders
- Prof. Jillian Kril
-
15. Motor neurone disease: molecular basis
- Prof. Kevin Talbot
-
16. Alzheimer's disease (AD)
- Prof. John Hodges
-
17. Frontotemporal dementia syndromes
- Prof. John Hodges
-
18. Motor neurone disease: clinical aspects
- Prof. Kevin Talbot
-
19. Neuro-imaging in dementia: using MRI in routine work-up
- Prof. Philip Scheltens
-
20. Prion diseases
- Prof. Pierluigi Gambetti
-
21. Mitochondrial disorders and neurodegeneration
- Prof. Anthony Schapira
-
23. Mutations in parkinsonian syndromes
- Dr. Andrew Singleton
-
25. Frontotemporal dementia
- Prof. Bruce Miller
Printable Handouts
Navigable Slide Index
- Introduction
- Positron-Emission-Tomography (PET)
- Scope of Brain PET
- FDG-PET: Normal cerebral glucose metabolism
- Frequent neurodegenerative diseases with characteristic FDG PET findings
- Imaging of local brain function
- FDG-PET: Progression of early-onset Alzheimer’s disease (AD)
- Automatic detection of abnormal metabolism and regions that are typically affected by AD
- Accuracy of FDG PET: diagnosis of probable AD
- Posterior cingulate cortex (PCC) impairment in Alzheimer’s disease
- Posterior cingulate cortex (PCC)
- Regional correlations (within left hemisphere)
- Comparison of CMRGlc reduction due to age and AD
- Frontal brain areas show reduced glucose metabolism in depression
- Progressive prosopagnosia
- Anosognosia in AD: metabolic changes related to patients' self assessment
- Scope of brain PET
- High-affinity amyloid PET tracers
- Imaging cerebral amyloid
- 18F-florbetapir: loss of g/w contrast as diagnostic criterion for amyloid deposition
- Amyloid pathology and resilience to AD
- Tau PET (18F-AV-1451)
- Frontotemporal lobar atrophies
- Genetics and pathology
- Fronto-temporal dementia with Amyotrophic Lateral Sclerosis
- Frontotemporal dementia and asymmetric frontotemporal atrophy
- Scope of brain PET
- Tracers for the dopaminergic system
- Anatomy of the dopaminergic system
- Mild Parkinson’s disease (HY2)
- Striatonigral degeneration (SD) compared to Parkinson's disease (PD)
- Progressive supranuclear palsy
- Chorea Huntington
- FDG PET metabolic signatures
- Cholinergic systems
- PET-tracers for the cholinergic system
- AChE activity measured by C-11-MP4A
- Dementia with Lewy Bodies (DLB)
- Transmitter deficits in Lewy body dementia:
- Cholinergic vs. dopaminergic deficit in Parkinson‘s disease and Dementia with Lewy bodies (DLB)
- Systems impairment in degenerative dementia
- Clinical PET tracers for neurodegenerative diseases
Topics Covered
- Brain imaging with positron emission tomography (PET) for dementia diagnosis and research
- Cerebral glucose metabolism in mild cognitive impairment, Alzheimer’s disease, dementia with Lewy bodies, frontotemporal dementia & depression
- Imaging of pathological markers (beta-amyloid and tau) in Alzheimer’s disease
- Imaging of neurotransmitters and receptors, in the dopaminergic and cholinergic system
- Multiple systems profiling in dementia, Parkinson’s and related motor disorders
Links
Series:
- Neurodegenerative Diseases
- Periodic Reports: Advances in Clinical Interventions and Research Platforms
Categories:
Therapeutic Areas:
Talk Citation
Herholz, K. (2020, October 29). Molecular brain imaging (PET) in diseases with dementia [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 6, 2024, from https://doi.org/10.69645/HAVF8652.Export Citation (RIS)
Publication History
Financial Disclosures
- There are no commercial/financial matters to disclose .
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is Karl Herholz.
I'm a professor in Clinical Neuroscience at the University of Manchester.
This presentation is about molecular brain imaging
with PET in diseases that may lead to dementia.
It is mainly based on studies done at
the Max-Planck Institute for Neurological Research in Cologne,
Germany, where I have been working for many years before moving to Manchester.
0:25
Let me start with an explanation of positron emission tomography,
which is usually abbreviated as PET.
It is based on short living positron emitting isotopes which are produced by a cyclotron.
Commonly used isotopes are carbon-11 and fluorine-18.
They are coupled to various small amounts typically
micrograms of biomolecules for production of radiopharmaceuticals.
These are briefly called radiotracers or simply tracers.
They can be applied to humans,
usually by intravenous injection.
They act like contrast agent,
but the amounts are so small that they have
no pharmacological actions and side effects are extremely rare.
They emit positrons which annihilate with electrons.
Imaging by a PET scanner is then based on the resulting gamma radiation.
It represents quantitatively the in
vivo distribution of the tracer in the body or in our case,
especially in the brain.
From that distribution, local metabolic rates or
receptor binding potentials can be calculated using physiological modeling.
1:40
The scope of brain PET imaging is enormous.
It allows imaging of neuronal function and of specific neurotransmitters and receptors.
In addition, at the logical proteins and cellular markers can also be displayed.
Thus, PET provides images of brain function as well of underlying molecular mechanisms.
Let's start with images of brain function.